Preemptive treatment of early donor-specific antibodies with IgA- and IgM-enriched intravenous human immunoglobulins in lung transplantation

Lobo, 2013, Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation, J Heart Lung Transplant., 32, 70, 10.1016/j.healun.2012.10.007 Smith, 2014, Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation, J Heart Lung Transplant., 33, 1074, 10.1016/j.healun.2014.02.033 Ius, 2014, Early-donor-specific antibodies in lung transplantation: risk factors and impact on survival, J Heart Lung Transplant., 33, 1255, 10.1016/j.healun.2014.06.015 Safavi, 2014, De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation, J Heart Lung Transplant., 33, 1273, 10.1016/j.healun.2014.07.012 Morrell, 2014, De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation, J Heart Lung Transplant., 33, 1288, 10.1016/j.healun.2014.07.018 Roux, 2016, Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics, Am J Transplant., 16, 1216, 10.1111/ajt.13589 Le Pavec, 2016, De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with worse outcomes, J Heart Lung Transplant., 35, 1067, 10.1016/j.healun.2016.05.020 Reinsmoen, 2017, A 3-center study reveals new insights into the impact of non-HLA antibodies on lung transplantation outcome, Transplantation., 101, 1215, 10.1097/TP.0000000000001389 Levine, 2016, Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant., 35, 397, 10.1016/j.healun.2016.01.1223 Westall, 2014, Antibody-mediated rejection in lung transplantation: fable, spin, or fact?, Transplantation., 98, 927, 10.1097/TP.0000000000000392 Hachem, 2010, Anti-HLA antibodies and preemptive antibody-directed therapy after lung transplantation, J Heart Lung Transplant., 29, 973, 10.1016/j.healun.2010.05.006 Witt, 2013, Acute antibody-mediated rejection after lung transplantation: a retrospective, single center, case series, J Heart Lung Transplant., 32, 1034, 10.1016/j.healun.2013.07.004 Ius, 2015, Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation, J Heart Lung Transplant., 34, 50, 10.1016/j.healun.2014.09.019 Ius, 2016, IgM-enriched human intravenous immunoglobulin-based treatment of patients with early donor specific anti-HLA antibodies after lung transplantation, Transplantation., 100, 2682, 10.1097/TP.0000000000001027 Tinckam, 2015, Survival in sensitized lung transplant recipients with perioperative desensitization, Am J Transplant., 15, 417, 10.1111/ajt.13076 Islam, 2017, Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation, Clin Transplant., 31, e13028, 10.1111/ctr.13028 Vacha, 2017, Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: does it work?, Clin Transplant., 31, e12886, 10.1111/ctr.12886 Lee, 2010, Primary graft dysfunction: definition, risk factors, short- and long-term outcomes, Semin Respir Crit Care Med., 31, 161, 10.1055/s-0030-1249111 Verleden, 2015, Impact of CLAD phenotype on survival after lung re-transplantation: a multicenter study, Am J Transplant., 15, 2223, 10.1111/ajt.13281 Stewart, 2007, Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection, J Heart Lung Transplant., 26, 1229, 10.1016/j.healun.2007.10.017 Walpen, 2004, Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum, Xenotransplantation., 11, 141, 10.1046/j.1399-3089.2003.00098.x Blackstone, 2002, Comparing apples and oranges, J Thorac Cardiovasc Surg., 123, 8, 10.1067/mtc.2002.120329 Jordan, 2011, Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients, Am J Transplant., 11, 196, 10.1111/j.1600-6143.2010.03400.x Tedla, 2015, Intravenous immunoglobulin in kidney transplantation, Curr Opin Organ Transplant., 20, 630, 10.1097/MOT.0000000000000250 Koenig, 2016, B cells and antibodies in transplantation, Transplantation., 100, 1460, 10.1097/TP.0000000000001069 Lobo, 2016, Role of natural autoantibodies and natural IgM anti-leucocyte autoantibodies in health and disease, Front Immunol., 7, 198, 10.3389/fimmu.2016.00198 Djoumerska, 2005, Serum IgM, IgG and IgA block by F(ab′)-dependent mechanism the binding of natural IgG autoantibodies from therapeutic immunoglobulin preparations to self-antigen, Eur J Haematol., 74, 101, 10.1111/j.1600-0609.2004.00350.x Jordan, 2011, Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation, Expert Rev Clin Immunol., 7, 341, 10.1586/eci.11.10 Shevach, 2009, Mechanisms of foxp3 + T regulatory cell-mediated suppression, Immunity., 30, 636, 10.1016/j.immuni.2009.04.010